Business
Medical Marijuana, Inc Major Investment AXIM Biotech Enters Agreement With Israel-Based CRO To Begin Clinical POC Study For Treatment Of Restless Leg Syndrome
Medical Marijuana, Inc Major Investment AXIM Biotech Enters Agreement With Israel-Based CRO To Begin Clinical POC Study For Treatment Of Restless Leg Syndrome.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\n\n\n\nMedical Marijuana, Inc Major Investment AXIM Biotech Enters Agreement With Israel-Based CRO To Begin Clinical POC Study For Treatment Of Restless Leg Syndrome\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMedical Marijuana, Inc Major Investment AXIM Biotech Enters Agreement With Israel-Based CRO To Begin Clinical POC Study For Treatment Of Restless Leg Syndrome\nPR Newswire\nSAN DIEGO, July 27, 2017\n\n\n\nSAN DIEGO, July 27, 2017 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, today announced that its major investment AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC: AXIM) has entered into a Services Agreement with an Israel-based contract research organization (CRO) to begin a clinical proof of concept study (POC) with its cannabidiol (CBD) and Gabapentin chewing gum product to treat restless leg syndrome (RLS) in patients.\n\nThe PK and double blind, randomized, single-center phase 2 trial will demonstrate the efficacy of AXIM's chewing gum product composed of Gabapentin and CBD on around 30 study participants to treat RLS. The CRO is conducting the trial in Israel.\n\n\"We are proud to support AXIM Biotech as the company continues to identify new clinical applications for its proprietary chewing gum product,\" said Medical Marijuana, Inc. CEO Dr. Stuart Titus. \"Research shows that RLS may be related to abnormalities in the nervous system, and even the U.S. Department of Health and Human Services has a patent titled 'Cannabinoids as Antioxidants and Neuroprotectants.' We believe that advancements in clinical cannabinoid research may hold keys to helping people experience symptomatic relief from challenging and debilitating neurological disorders.\"\n\nRestless leg syndrome (RLS), also known as Willis–Ekbom Disorder (WED), is a condition associated with nocturnal sensorimotor symptoms, or nocturnal spasms of the muscles of the lower extremities, that can result in significant sleep disruption and severe pain. RLS is a prevalent condition, affecting an estimated 3.9–14.3 % of...